Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 365,306 | 254,061 | 228,724 | 125,449 | 156,366 |
| Depreciation Amortization | 234,924 | 198,095 | 161,779 | 131,159 | 126,658 |
| Income taxes - deferred | -133 | -21,895 | -9,702 | 28,254 | 1,945 |
| Accounts receivable | -85,627 | -8,323 | -21,196 | -48,279 | -52,780 |
| Accounts payable and accrued liabilities | 748 | 29,775 | -12,732 | 34 | 22,076 |
| Other Working Capital | -26,275 | 6,179 | 14,814 | 5,943 | -13,494 |
| Other Operating Activity | 57,632 | 23,044 | 79,453 | 75,514 | 76,128 |
| Operating Cash Flow | $546,575 | $480,936 | $441,140 | $318,074 | $316,899 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -26,692 | -22,341 | -25,125 | -46,217 | -40,248 |
| PPE Investments | -166,560 | -140,514 | -140,054 | -82,431 | -55,288 |
| Net Acquisitions | -418,628 | -515,701 | -824,868 | 47,450 | -648,482 |
| Sale Of Investment | 11,401 | 942 | 35,849 | 9,128 | 47,652 |
| Other Investing Activity | -1,065 | -3,888 | -805 | -516 | 3,694 |
| Investing Cash Flow | $-601,544 | $-681,502 | $-955,003 | $-72,586 | $-692,672 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,230,988 | 3,358,461 | 2,755,028 | 236,856 | 1,044,666 |
| Debt Repayment | -2,200,400 | -3,131,181 | -2,201,003 | -372,435 | -656,636 |
| Common Stock Issued | 46,586 | 34,546 | 37,657 | 38,870 | 23,197 |
| Common Stock Repurchased | -23,979 | -18,087 | -13,846 | -106,909 | -12,267 |
| Other Financing Activity | -5,947 | -11,802 | -19,777 | -4,858 | -18,204 |
| Financing Cash Flow | $47,248 | $231,937 | $558,059 | $-208,476 | $380,756 |
| Exchange Rate Effect | 794 | 11,357 | -9,474 | 11,234 | -2,996 |
| Beginning Cash Position | 240,046 | 197,318 | 166,331 | 119,894 | 119,963 |
| End Cash Position | 233,119 | 240,046 | 197,318 | 166,331 | 119,894 |
| Net Cash Flow | $-6,927 | $42,728 | $30,987 | $46,437 | $-69 |
| Free Cash Flow | |||||
| Operating Cash Flow | 546,575 | 480,936 | 441,140 | 318,074 | 316,899 |
| Capital Expenditure | -166,560 | -140,514 | -140,054 | -82,431 | -55,288 |
| Free Cash Flow | 380,015 | 340,422 | 301,086 | 235,643 | 261,611 |